Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Organizacion Soriana SAB de CV
BMV:SORIANAB
|
MX |
|
Thor Industries Inc
NYSE:THO
|
US |
|
Biocept Inc
OTC:BIOCQ
|
US |
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
AU |
Spexis AG
Other
Spexis AG
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Spexis AG
SIX:SPEX
|
Other
-CHf406k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Other
-CHf2k
|
CAGR 3-Years
90%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
Spexis AG
Glance View
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
See Also
What is Spexis AG's Other?
Other
-406k
CHF
Based on the financial report for Dec 31, 2023, Spexis AG's Other amounts to -406k CHF.
What is Spexis AG's Other growth rate?
Other CAGR 5Y
48%
Over the last year, the Other growth was -107%.
